tegoprazan + rivaroxaban

**Tegoprazan + rivaroxaban** is a combination of two drugs: tegoprazan, a potassium-competitive acid blocker (P-CAB) used as an alternative to proton pump inhibitors for the treatment of acid-related gastrointestinal conditions, and rivaroxaban, a direct oral anticoagulant (DOAC) that acts as a selective inhibitor of factor Xa, preventing thrombin generation and clot formation. Tegoprazan decreases gastric acid secretion by antagonizing potassium at the gastric H+/K+ ATPase, providing gastrointestinal protection, especially in patients at risk of bleeding. Rivaroxaban inhibits factor Xa in the coagulation cascade to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and for prophylaxis in atrial fibrillation. This combination may be considered in clinical contexts needing both gastric acid suppression and anticoagulation, such as patients with a history of gastrointestinal bleeding on anticoagulant therapy[1][2][3].

Other names

tegoprazanrivaroxaban